Navigation Links
Trovagene to Present at Two Healthcare Conferences
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2013 healthcare conferences: Rodman & Renshaw and Stifel.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Rodman & Renshaw 15th Annual Global Healthcare ConferenceTrovagene is scheduled to present at the 15th Annual Rodman & Renshaw Global Healthcare Conference at the Millennium Broadway Hotel in New York, NY on Monday, September 9, 2013 at 3:15 p.m. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://www.wsw.com/webcast/rrshq23/TROV and can also be accessed through the investor relations page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days.

Stifel Healthcare Conference 2013Trovagene is scheduled to present at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, MA on Wednesday, September 11, 2013 at 10:20 a.m. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://www.veracast.com/webcasts/stifel/healthcare2013/92105578306.cfm and can also be accessed through the investor relations page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days.

About Trovagene, Inc.Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.ContactTrovagene, Inc.FinancialInvestor RelationsStephen Zaniboni

Chief Financial OfficerAmy Caterina

Investor RelationsTrovagene, Inc.Trovagene, Inc.858-952-7594858-952-7593szaniboni@trovagene.comacaterina@trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Trovagene to Present at Leerink Swan Global Healthcare Conference
2. Trovagene to be Added to Russell Microcap Index
3. Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
4. Trovagene and Strand Life Sciences Plan Collaboration to Validate and Offer Urine-Based HPV Screening Test in India and South Asia
5. TrovaGene Acquires CLIA - Certified Laboratory
6. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
7. Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference
8. Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
9. ANP to present at and attend major US investment, partnering and industry conferences
10. Cambridge Semantics to Present on ‘Smart Data’ During Deep-Dive Workshop at 2013 Big Data Innovation Summit
11. EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... will deliver a talk on its first-in-class technologies for tissue stem cell counting ... on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. ...
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu Scientific Instruments ... Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to ... more. Expo attendees can stop by booth 1021 to learn how Shimadzu’s instruments ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April 27, ... ) announced today that Martine Rothblatt , Ph.D., ... provide an overview and update on the company,s business ... Care Conference. The presentation will take place ... Time, and can be accessed via a live webcast ...
(Date:4/27/2016)... Winnipeg, Manitoba (PRWEB) , ... April 27, 2016 ... ... commercially released for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance ... for better understanding disease and testing novel treatments in small animal subjects. Simultaneous ...
Breaking Biology Technology:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
Breaking Biology News(10 mins):